Inhibition of colon cancer K-RasG13D mutation reduces cancer cell proliferation but promotes stemness and inflammation via RAS/ERK pathway
K-Ras is a well-studied oncogene, and its mutation is frequently found in epithelial cancers like pancreas, lung, and colorectal cancers. Cancer cells harboring K-Ras mutations are difficult to treat due to the drug resistance and metastasis properties. Cancer stem cells (CSCs) are believed the majo...
Main Authors: | Yan Qi, Hong Zou, XiaoHui Zhao, Joanna Kapeleris, Michael Monteiro, Feng Li, Zhi Ping Xu, Yizhen Deng, Yanheng Wu, Ying Tang, Wenyi Gu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.996053/full |
Similar Items
-
Oncogenic K‐RasG12V cannot overcome proliferation failure caused by loss of Ppp6c in mouse embryonic fibroblasts
by: Mai Ito, et al.
Published: (2024-04-01) -
Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy
by: Ozge Tatli, et al.
Published: (2021-12-01) -
Effect of ginsenoside CK combined with cisplatin on the proliferation and migration of human cervical cancer HeLa cells via Ras/ERK/MAPK pathway
by: Xiao-Li Li, et al.
Published: (2023-03-01) -
The Predictive and Prognostic Role of RAS–RAF–MEK–ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets
by: Andrea Rocca, et al.
Published: (2022-10-01) -
Sanguisorba officinalis L. enhances the 5-fluorouracil sensitivity and overcomes chemoresistance in 5-fluorouracil-resistant colorectal cancer cells via Ras/MEK/ERK and PI3K/Akt pathways
by: Weijia Zhang, et al.
Published: (2023-06-01)